An optogenetic gene therapy increased retinal light sensitivity by a factor of 2.0 to 62.3 in seven of 10 blind patients with late-stage retinitis pigmentosa, according to results published in the New England Journal of Medicine. Six of those seven reached what the researchers classify as a clinically meaningful improvement.

The study, led by José-Alain Sahel of the University of Pittsburgh School of Medicine and director of the UPMC Vision Institute, together with Botond Roska of the Institute of Molecular and Clinical Ophthalmology Basel (IOB), is the largest human test of optogenetics for vision restoration to date. It follows a first-in-human demonstration in a single blind patient in 2021, published in Nature Medicine, that showed partial recovery of visual function.

The publication lands the same week the inventors of optogenetics received the 2026 Nobel Prize in Physiology or Medicine — a coincidence that will not hurt commercial interest in the platform.

How does the therapy work?

Retinitis pigmentosa is an inherited degenerative condition that destroys photoreceptors — the rods and cones — and can end in irreversible blindness. Sahel notes that the disease can trace to mutations in any one of hundreds of genes, which is precisely why optogenetics fits: it does not depend on the underlying mutation.

"Although patients with retinitis pigmentosa lose their rod and cone cells, which normally detect light, many other cells within the retina can remain present for years after vision loss," Sahel said. "Optogenetics enables us to introduce a light-sensitive protein into these surviving cells, allowing them to respond to light and transmit visual information to the brain."

The treatment has two components:

• A one-time intravitreal injection of a gene encoding ChrimsonR, a light-sensitive protein with peak response around 590 nm (amber), delivered into surviving retinal ganglion cells.
• Camera-equipped goggles that convert pixel-by-pixel changes in light intensity into pulses of amber light projected onto the retina, activating the modified cells.

The approach bypasses damaged photoreceptors entirely and exploits retinal circuits that remain intact.

What did the trial measure?

The trial enrolled 10 participants blinded by advanced retinitis pigmentosa, each injected in their worse-seeing eye. They were split into three dose-escalation groups receiving 5.0 × 10¹⁰, 1.5 × 10¹¹ or 5.0 × 10¹¹ vector genomes per eye.

Safety was the primary endpoint. The team recorded 33 mild and moderate ocular adverse events — including temporary inflammation and rises in eye pressure — across nine participants, plus one severe event that resolved within minutes of treatment. Their conclusion: within the study's limits, the treatment is safe.

Functional results came from goggle-based vision testing before and after injection:

• Light sensitivity rose in seven of 10 participants, by factors of 2.0 to 62.3; six showed clinically meaningful improvement.
• In a task to detect, localize and touch a notebook, five of eight participants scored higher with the goggles than without; four improved on a staple-box version.
• In a single-bar orientation task, five of eight participants were more accurate with the goggles.

To separate genuine visual processing from artefact, the researchers recorded EEG signals in five patients during two tests: detecting a tumbler with eyes open or closed, and passive viewing of periodic visual stimuli. In the tumbler test, EEG decoding accuracy was higher with goggles only when eyes were open — evidence that the improvement reflects real visual processing, not measurement noise. Decoding accuracy in the second test correlated with behavioural gains on the notebook and staple-box tasks.

What are the caveats?

The researchers themselves flag the limits. Functional changes were modest: the therapy improved object detection and discrimination, not normal sight. And with 10 participants, the cohort is too small to characterise treatment response fully or compare dose groups with statistical confidence.

One operational finding matters for anyone planning clinical deployment: participants who spent longer training with the goggles performed better on behavioural tests. The device component, in other words, carries a real learning curve — a budget and patient-management consideration for any future trial.

What comes next?

Two development tracks are already running. At the Institut de la Vision in Paris, Valentina Emiliani's team is building digital holographic goggles with an eye tracker that will project 20 µm-wide images capable of stimulating individual retinal cells. "With the eye tracker, we can make sure we are projecting exactly onto the area of the retina that we want. We've already developed a prototype, and it is moving forward," Sahel said.

In parallel, Pittsburgh scientists working with Roska's group are developing cell-specific gene therapy vectors to discriminate between retinal cell types. "Some respond to the onset of light, some to the offset of light, some to movement and direction," Sahel explained. "We are trying to selectively stimulate the 'on' and the 'off', and discriminate the signal we are sending."

"We are optimistic about advancing this approach toward future clinical trials," he said — a signal that a larger, dose-optimised study is the logical next milestone for this platform.